A Study in People With Systemic Sclerosis to Test Whether Avenciguat (BI

Status Recruiting

Clinical Trial Summary

This study is open to adults aged 18 and older or above legal age who have systemic sclerosis. People can participate if they have a specific subtype called diffuse cutaneous systemic sclerosis. People with another subtype called limited cutaneous systemic sclerosis can also participate if they are anti Scl-70 antibody positive. Systemic sclerosis is also called scleroderma. The purpose of this study is to find out whether a medicine called Avenciguat (BI 685509) helps people with scleroderma who have symptoms due to lung fibrosis or vascular problems. Participants are put into 2 groups by chance. One group takes Avenciguat (BI 685509) tablets 3 times a day and the other group takes placebo tablets 3 times a day. Placebo tablets look like BI 685509 tablets but do not contain any medicine. Participants take the tablets for at least 11 months. Afterwards, participants can continue to take the tablets until the last participant has completed the 11-months treatment period. This means that the time in the study and duration of treatment is different for each participant, depending on when they start the study. At the beginning of the study, participants visit the study site every 2 weeks. The time between the visits to the study site gets longer over the course of the study. After the 11-months treatment period, participants visit the study site every 3 months. During the study, participants regularly do lung function tests. The results are compared between the 2 groups to see whether the treatment works. The participants also regularly fill in questionnaires about their scleroderma symptoms. The doctors regularly check participants' skin condition and general health and take note of any unwanted effects.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05559580
Study type	Interventional
Source	Boehringer Ingelheim
Contact	Boehringer Ingelheim
Phone	1-800-243-0127
Email	clintriage.rdg@boehringer-ingelheim.com
Status	Recruiting
Phase	Phase 2
Start date	November 24, 2022
Completion date	November 28, 2025

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03965780` - The SPIN - Scleroderma Support Group Leader EDucation Program Trial (SPIN-SSLED)	N/A
Terminated	`NCT02558543` - Subcutaneous Injection of Autologous Adipose Tissue-derived Stromal Vascular Fraction Into the Fingers of Patients With Systemic Sclerosis	Phase 2
Withdrawn	`NCT01202045` - Stress Echocardiography in the Detection of Pulmonary Arterial Hypertension in Systemic Sclerosis Patients	N/A
Terminated	`NCT01445821` - Autologous Stem Cell Systemic Sclerosis Immune Suppression Trial	Phase 3
Recruiting	`NCT05878717` - A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease	Phase 3
Recruiting	`NCT03559465` - Profibrosing Role of B Lymphocytes in Patients With Systemic Sclerosis.	N/A
Not yet recruiting	`NCT03610217` - Pragmatic Clinical Trials in Scleroderma	N/A
Completed	`NCT02655640` - The Impact of Illness Perceptions on Health Related Outcomes in Patients With Lupus and Systemic Sclerosis	N/A
Completed	`NCT05622578` - Phenotyping of Chronic Pain in Diffused Systemic Scleroderma	N/A
Recruiting	`NCT04804930` - Trichoscopy and Systemic Scleroderma
Completed	`NCT03675581` - A Study to Test Whether Nintedanib Influences the Components of Birth-control Pills in Women With Systemic Sclerosis Associated Interstitial Lung Disease (SSc-ILD)	Phase 1
Completed	`NCT03221257` - Scleroderma Lung Study III - Combining Pirfenidone With Mycophenolate	Phase 2
Completed	`NCT00442611` - A Study to Evaluate the Safety and Efficacy of Abatacept in Patients With Diffuse Systemic Sclerosis (Scleroderma)	Phase 1/Phase 2
Completed	`NCT00001330` - Study of Silicone-Associated Connective Tissue Diseases	N/A
Completed	`NCT02597933` - A Trial to Compare Nintedanib With Placebo for Patients With Scleroderma Related Lung Fibrosis	Phase 3
Not yet recruiting	`NCT05821335` - Leap Motion Based Gamefication Exercises in the Individuals With Systemic Sclerosis	N/A
Completed	`NCT00333437` - Pulmonary Involvement in Scleroderma: A Clinical Study of the Safety and Efficacy of Mycophenolate Mofetil in Scleroderma Patients With Lung Involvement	N/A
Completed	`NCT00025818` - Six Month Clinical Research Study for Patients With Moderate or Severe Dry Eye Syndrome	Phase 3
Not yet recruiting	`NCT05351060` - Novel Splinting Technique Using 3D Models	N/A
Not yet recruiting	`NCT04563481` - Effectiveness of Telerehabilitation on Scleroderma	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

A Study in People With Systemic Sclerosis to Test Whether Avenciguat (BI 685509) Has an Effect on Lung Function and Other Systemic Sclerosis Symptoms — VITALISScE™

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms